The first quarter of 2018 report of Jianfeng Group
Release time:
2021-01-05
公司代码:600668 公司简称:尖峰集团
浙江尖峰集团股份有限公司
2018年第一季度报告正文
一、 重要提示
1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
1.2 公司全体董事出席董事会审议季度报告。
1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人(会计主管人员)吴德富保证季度报告中财务报表的真实、准确、完整。
1.4 本公司第一季度报告未经审计。
二、 公司主要财务数据和股东变化
2.1 主要财务数据
单位:元 币种:人民币
|
|
本报告期末 |
上年度末 |
本报告期末比上年度末增减(%) |
|
总资产 |
4,366,775,455.41 |
4,175,730,846.73 |
4.58 |
|
归属于上市公司股东的净资产 |
2,757,802,176.89 |
2,627,318,888.65 |
4.97 |
|
|
年初至报告期末 |
上年初至上年报告期末 |
比上年同期增减(%) |
|
经营活动产生的现金流量净额 |
13,967,176.23 |
317,755.25 |
4,295.58 |
|
|
年初至报告期末 |
上年初至上年报告期末 |
比上年同期增减(%) |
|
营业收入 |
669,522,008.06 |
566,846,953.96 |
18.11 |
|
归属于上市公司股东的净利润 |
104,344,646.12 |
112,200,485.23 |
-7.00 |
|
归属于上市公司股东的扣除非经常性损益的净利润 |
98,932,514.65 |
108,827,872.82 |
-9.09 |
|
加权平均净资产收益率(%) |
3.89 |
4.57 |
减少0.68个百分点 |
|
基本每股收益(元/股) |
0.3032 |
0.3260 |
-7.00 |
|
稀释每股收益(元/股) |
0.3032 |
0.3260 |
-7.00 |
非经常性损益项目和金额
单位:元 币种:人民币
|
项目 |
本期金额 |
说明 |
|
非流动资产处置损益 |
-25,888.87 |
|
|
越权审批,或无正式批准文件,或偶发性的税收返还、减免 |
|
|
|
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 |
6,648,601.60 |
|
|
委托他人投资或管理资产的损益 |
270,624.68 |
|
|
除上述各项之外的其他营业外收入和支出 |
-166,308.37
|
|
|
少数股东权益影响额(税后) |
-196,583.34 |
|
|
所得税影响额 |
-1,118,314.23 |
|
|
合计 |
5,412,131.47 |
|
2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
单位:股
|
股东总数(户) |
27,298 |
||||||
|
前十名股东持股情况 |
|||||||
|
股东名称(全称) |
期末持股 数量 |
比例(%) |
持有有限售条件股份数量 |
质押或冻结情况 |
股东性质 |
||
|
股份状态 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
16.15 |
0 |
无 |
0 |
国有法人 |
|
|
新余中盛恒兴投资管理合伙企业(有限合伙 |
17,158,922 |
4.99 |
0 |
无 |
0 |
未知 |
|
|
新余汇恒瑞投资管理合伙企业(有限合伙) |
12,665,208 |
3.68 |
0 |
无 |
0 |
未知 |
|
|
香港中央结算有限公司 |
4,372,091 |
1.27 |
0 |
无 |
0 |
未知 |
|
|
刘锦春 |
3,874,269 |
1.13 |
0 |
无 |
0 |
境内自然人 |
|
|
钟以隆 |
3,584,000 |
1.04 |
0 |
无 |
0 |
境内自然人 |
|
|
苏志伟 |
3,226,848 |
0.94 |
0 |
无 |
0 |
境内自然人 |
|
|
王晓红 |
3,121,943 |
0.91 |
0 |
无 |
0 |
境内自然人 |
|
|
骆惠娟 |
2,726,200 |
0.79 |
0 |
无 |
0 |
境内自然人 |
|
|
中国工商银行股份有限公司-南方大数据100指数证券投资基金 |
2,667,200 |
0.78 |
0 |
无 |
0 |
未知 |
|
|
前十名无限售条件股东持股情况 |
|||||||
|
股东名称 |
持有无限售条件流通股的数量 |
股份种类及数量 |
|||||
|
种类 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
人民币普通股 |
55,564,103 |
||||
|
新余中盛恒兴投资管理合伙企业(有限合伙 |
17,158,922 |
人民币普通股 |
17,158,922 |
||||
|
新余汇恒瑞投资管理合伙企业(有限合伙) |
12,665,208 |
人民币普通股 |
12,665,208 |
||||
|
香港中央结算有限公司 |
4,372,091 |
人民币普通股 |
4,372,091 |
||||
|
刘锦春 |
3,874,269 |
人民币普通股 |
3,874,269 |
||||
|
钟以隆 |
3,584,000 |
人民币普通股 |
3,584,000 |
||||
|
苏志伟 |
3,226,848 |
人民币普通股 |
3,226,848 |
||||
|
王晓红 |
3,121,943 |
人民币普通股 |
3,121,943 |
||||
|
骆惠娟 |
2,726,200 |
人民币普通股 |
2,726,200 |
||||
|
中国工商银行股份有限公司-南方大数据100指数证券投资基金 |
2,667,200 |
人民币普通股 |
2,667,200 |
||||
|
上述股东关联关系或一致行动的说明 |
本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系,也未知是否属于《上市公司收购管理办法》规定的一致行动人。 |
||||||
|
表决权恢复的优先股股东及持股数量的说明 |
不适用 |
||||||
2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表
三、 重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
|
单位:万元 |
||||
|
资产负债表项目 |
期末数 |
期初数 |
变动幅度 |
变动原因 |
|
预付款项 |
9,726.83 |
4,610.82 |
110.96% |
主要系本报告期子公司预付货款增加所致。 |
|
应收股利 |
2,076.00 |
|
100.00% |
主要系报告期公司按被投资单位天士力控股集团有限公司2017年度利润分配的股东会决议计入应收的现金股利所致。 |
|
其他应收款 |
1,997.52 |
1,308.75 |
52.63% |
主要系报告期公司及子公司存出保证金增加所致。 |
|
其他流动资产 |
925.10 |
1,328.92 |
-30.39% |
主要系报告期子公司抵扣了上年取得的留抵进项税所致。 |
|
短期借款 |
16,800.00 |
8,900.00 |
88.76% |
主要系报告期公司银行贷款增加所致。 |
|
应付职工薪酬 |
1,279.67 |
3,627.55 |
-64.72% |
主要系报告期公司及子公司发放上年末计提的年终奖所致。 |
|
应付利息 |
1,579.21 |
934.17 |
69.05% |
主要系报告期公司计提应付债券利息以及由于银行借款增加相应计提利息增加所致。 |
|
应付股利 |
2,520.16 |
120.16 |
1997.38% |
主要系报告期子公司股东会决议已宣告发放2017年度现金股利所致。 |
|
利润表项目 |
本期数 |
上年同期数 |
变动幅度 |
变动原因 |
|
税金及附加 |
551.67 |
336.88 |
63.76% |
主要系报告期子公司应交税费增加所致。 |
|
销售费用 |
10,678.03 |
4,772.03 |
123.76% |
主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整,公司销售费用中增加了市场推广费和其他支出。 |
|
投资收益 |
1,950.22 |
6,087.10 |
-67.96% |
主要系报告期公司联营投资单位天士力控股集团有限公司利润大幅减少,公司权益法核算计入投资收益相应减少所致。 |
|
其他收益 |
502.73 |
0.00 |
100.00% |
主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助从“营业外收入”科目转入所致。 |
|
营业外收入 |
171.06 |
485.84 |
-64.79% |
主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助转入“其他收益”项目所致。 |
|
营业外支出 |
27.23 |
4.66 |
483.87% |
主要系报告期子公司营业外支出增加所致。 |
|
所得税费用 |
3,098.44 |
1,981.63 |
56.36% |
主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。 |
|
现金流量表项目 |
|
|
|
|
|
经营活动产生的现金流量净额 |
1,396.72 |
31.78 |
4295.58% |
主要系报告期由于公司经营活动现金流入增加所致。 |
|
投资活动产生的现金流量净额 |
-9,823.08 |
-2,287.17 |
|
主要系报告期子公司对外投资及在建项目投入增加所致。 |
|
筹资活动产生的现金流量净额 |
7,779.59 |
-210.06 |
|
主要系报告期公司增加了银行借款所致。 |
3.2 重要事项进展情况及其影响和解决方案的分析说明
1、2017年2月28日,公司九届10次董事会通过了《关于子公司对外投资的议案》,公司控股子公司尖峰药业拟以增资和股权转让的方式分期对北慧生物进行投资;2018年3月31日,公司披露了对外投资进展情况。上述事项详见2017年3月1日、2018年3月31日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2017-003《关于子公司对外投资的公告》、临2018-003《关于子公司对外投资的进展公告》。
2、2018年1月19日,本公司十届2次董事会通过了《关于子公司尖峰药业对外投资的议案》,尖峰药业拟投资11132.79万元以收购股份和增资的方式对上海北卡进行投资。投资完成后,上海北卡注册资本由原来的1100万元增加至1755.55万元,其中尖峰药业占55%。上述事项详见2018年1月20日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-002《关于子公司尖峰药业对外投资的公告》。截止报告期末,尖峰药业已经按照协议约定,支付了第一期股权转让款和增资款。目前正在办理资产交接、工商变更登记手续。
3、2017年4月15日,公司九届11次董事会通过了《关于尖峰国贸新建仓库(电商物流园)项目的议案》,批准控股子公司尖峰国贸投资7500万元新建仓库(电商物流园)。2017年6月6日,公司九届13次董事会通过了《关于尖峰国贸仓库出租的议案》,同意尖峰国贸将该新建仓库(电商物流园)的仓库、堆场、停车场等物业出租给上海安能聚创供应链管理有限公司。上述事项详见2017年4月18日、2017年6月7日披露于上海证券交易所网站(http//:www.sse.com.cn/) 的临2017-006《九届11次董事会决议公告》和临2017-013《九届13次董事会决议公告》。截止3月底,该项目累计已投入资金3909.65万元。
3.3 报告期内超期未履行完毕的承诺事项
3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
|
公司名称 |
浙江尖峰集团股份有限公司 |
|
法定代表人 |
蒋晓萌 |
|
日期 |
2018年4月27日 |
- 发布时间: 2018-04-28
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05